Docetaxel

Docetaxel is a taxane antineoplastic medicine that interferes with microtubule function, an essential process involved in cell division. It binds to tubulin and promotes stabilization of microtubules, preventing their normal breakdown during mitosis and ultimately disrupting the division and survival of rapidly proliferating cells. Because normal tissues with rapidly dividing cells can also be affected, treatment may cause effects such as neutropenia, mucosal symptoms, hair loss and other toxicities. Docetaxel is administered by intravenous infusion, generally over approximately one hour, and is usually given at three-week intervals, although the exact regimen depends on the cancer and combination treatment being used. It is used either as a single agent or with other anticancer medicines, including doxorubicin, cyclophosphamide, cisplatin, fluorouracil and prednisone. Docetaxel has established roles in several major solid tumors, including breast cancer, non-small-cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric or gastroesophageal-junction adenocarcinoma, and locally advanced squamous cell carcinoma of the head and neck. Its clinical importance comes from its established cytotoxic activity and extensive evidence from randomized clinical trials across these cancer settings.

Docetaxel was developed as a semisynthetic taxane related to paclitaxel, with its development focused on improving taxane activity and pharmaceutical properties. The medicine was subsequently evaluated in multiple solid tumors, including breast, lung and prostate cancers. The U.S. FDA granted the original approval for docetaxel in 1996. Subsequent U.S. approvals expanded its use to additional cancer types and combination regimens, including metastatic castration-resistant prostate cancer in 2004. In the European Union, the EMA granted marketing authorisation for Taxotere, the reference docetaxel product, on November 27, 1995. Current regulatory labeling includes indications in breast cancer, non-small-cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma including gastroesophageal-junction adenocarcinoma, and locally advanced squamous cell carcinoma of the head and neck. Key clinical programs included studies supporting breast and lung cancer indications and the TAX 327 phase 3 program, which supported the prostate-cancer indication.

Docetaxel is used as single-agent therapy for locally advanced or metastatic breast cancer after failure of prior chemotherapy and for locally advanced or metastatic non-small-cell lung cancer after failure of platinum-based chemotherapy. In breast cancer, it is also used with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive disease. For unresectable, locally advanced or metastatic non-small-cell lung cancer that has not previously received chemotherapy for that condition, docetaxel may be combined with cisplatin. In metastatic castration-resistant prostate cancer, docetaxel is administered with prednisone. It is also used with cisplatin and fluorouracil for previously untreated advanced gastric adenocarcinoma, including gastroesophageal-junction adenocarcinoma, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck. The specific indication and combination should follow the applicable regulatory label and treatment protocol.

Docetaxel is administered intravenously, usually over one hour, with most established regimens given every three weeks. The dose varies by indication: commonly used adult regimens include 75 mg/m² for non-small-cell lung cancer, metastatic castration-resistant prostate cancer, adjuvant breast cancer and several combination regimens, while single-agent treatment of locally advanced or metastatic breast cancer may use 60–100 mg/m². In gastric cancer and some head and neck cancer regimens, docetaxel is administered on day 1 with cisplatin, followed by continuous-infusion fluorouracil according to the relevant protocol. Patients generally receive corticosteroid premedication, commonly dexamethasone, to reduce fluid retention and hypersensitivity reactions. Treatment duration depends on the indication and clinical response; adjuvant breast-cancer treatment is generally given for a defined number of cycles, whereas treatment of advanced disease is continued according to response, tolerance and disease progression. Dose modification or treatment interruption may be required for toxicity.

Common adverse effects of docetaxel include neutropenia and other reductions in blood-cell counts, anemia, infections, fatigue, nausea, vomiting, diarrhea, mouth inflammation, hair loss, nail changes, peripheral sensory neuropathy and muscle or joint pain. Fluid retention, including swelling of the legs or other areas, can occur and is an important characteristic toxicity. Changes in liver-function tests may also occur. When docetaxel is combined with other chemotherapy medicines, some adverse effects may result from the combination rather than docetaxel alone. The frequency and severity of side effects vary with dose, treatment combination, individual risk factors and previous therapy. Appropriate premedication, laboratory monitoring and supportive treatment can help manage many treatment-related effects.

Important serious risks include severe neutropenia, febrile neutropenia, serious infections, severe hypersensitivity or anaphylactic reactions, fluid retention, severe skin reactions, enterocolitis, peripheral neuropathy and liver toxicity. Docetaxel should not be administered to patients with a neutrophil count below the threshold specified in the prescribing information, and liver-function abnormalities can increase the risk of severe toxicity. Severe hypersensitivity reactions require immediate discontinuation and appropriate emergency management. Patients with significant hepatic impairment require particular caution, and some liver-function abnormalities are contraindications to treatment. Rare but serious complications can involve the gastrointestinal tract, lungs, nervous system or other organs. Treatment may need to be delayed, dose-adjusted or discontinued when clinically significant toxicity develops.

Before each treatment cycle, clinicians should review the patient's blood counts and liver-function tests and assess for infection, neuropathy, fluid retention and other clinically relevant toxicities. Docetaxel should be used cautiously in patients with hepatic impairment because elevated liver enzymes are associated with increased risk of severe adverse reactions. Corticosteroid premedication is routinely used unless contraindicated or modified for the specific regimen. Because docetaxel is metabolized predominantly through CYP3A4/5 pathways, concomitant medicines that strongly inhibit or induce these enzymes may alter docetaxel exposure and should be reviewed carefully. Concomitant administration with other myelosuppressive or neurotoxic therapies may also increase toxicity. Patients should receive appropriate infection-prevention advice during periods of neutropenia, and vaccination decisions should be coordinated with the treating oncology team. Docetaxel contains or may be formulated with polysorbate 80, and severe hypersensitivity to docetaxel or polysorbate 80 is a contraindication in applicable labeling.

Confirm the cancer indication, treatment protocol, baseline blood counts and hepatic function before administration. Ensure appropriate corticosteroid premedication is prescribed and taken at the required time because it reduces the risk and severity of fluid retention and hypersensitivity reactions. Administration should take place in a facility equipped to manage anaphylaxis and other acute chemotherapy complications. Monitor blood counts closely, particularly for neutropenia and febrile neutropenia, and assess liver function before subsequent cycles. Review concomitant medicines for potential CYP3A4 interactions and consider cumulative neurotoxicity when docetaxel is combined with other neurotoxic agents. Patients should be counselled to promptly report fever, chills, breathing difficulty, severe diarrhea, significant swelling, rash, mouth sores, numbness or tingling, and other new or worsening symptoms. Dose delays or modifications should follow the applicable prescribing information and institutional chemotherapy protocol.